News

McKesson's Chris Van Norman previews his LogiPharma USA keynote on demand signal sharing, AI, and precision distribution for targeted therapies.

LogiPharma's Charleen Ring and McKesson's Chris Van Norman preview the 2026 agenda, sessions to prioritize and a day two fireside chat.

Cardinal Health and McKesson moved to extend CVS Health distribution deals through June 2032, retaining their largest customer pending final contracts.

Inside the October 2026 issue: why splitting MMR takes years, why payers cite a price that does not bind them, and what pricing rules broke.

Mike Hennessy Jr. on the commercial assumptions being rewritten across pricing, patient engagement and supply chain in PC's October 2026 print issue.

In this Q&A, Doceree CEO Harshit Jain, MD, explains why AI should inform prescribing decisions, not drive them, and how sales reps own relationships while AI extends reach.

Patient support data that is trusted, connected and delivered into field workflows can move access teams from reporting to faster patient intervention.

In this week's Pharma Pulse, the EU Council adopts the "pharma package," Commerce details 0% tariffs for certain drugs and Sharp expands autoinjector assembly capacity.

GLP-1 demand is straining pharma cold chain capacity, from tighter temperature thresholds and rising load rejections to fuel costs and trailer backlogs.

Waltz Health and Fresenius Kabi will offer three biosimilars through a direct-to-payer model that bypasses traditional wholesaler and PBM rebate channels.

Eutecma's Tempaid buy pairs reusable bulk shippers with last-mile mailers as smaller, more frequent refrigerated shipments reshape demand.

HDA's Kala Shankle says a federal licensure baseline could bring real efficiency gains for wholesale distributors and 3PLs, but only if state requirements align and every stakeholder moves on the same timeline.

With HRSA's approval window now closed, attention turns to whether health system pharmacies can reconcile rebates at scale before the pilot's Jan. 1 start.

As patient expectations continue to evolve, brick-and-mortar pharmacy’s path forward lies in combining trusted, face-to-face care with the efficiency and convenience patients increasingly value.

Copeland's Dickson buy adds cloud-native monitoring as the pharma cold chain moves toward continuous visibility to meet rising regulatory demands.

In this week's Pharma Pulse, Vicapsys merges with Stateline, Veritiv targets GLP-1 shipping, Section 232 tariffs widen and HRSA's 340B rebate pilot deadline arrives.

Episode 3 of Supply Chain Signal examines the Aug. 31 MFN agreements with nine mid-size manufacturers, the GENEROUS Medicaid model and whether pricing, trade and manufacturing policy now add up to a new pharma operating model.

Cencora's Ameer Ali on the operational lift behind the 12-digit NDC shift, the readiness gap across manufacturers and what's at stake for product flow if systems aren't ready in time.

Temperature excursions cost pharma an estimated $35 billion a year as biologics, GLP-1s and cell and gene therapies raise cold chain stakes.

Valerie Bandy of Tecsys on where 340B rebate mechanics threaten pharmacy purchasing, and how stakeholders can prevent disruption.

CMS says 40 states and Puerto Rico have signed on to the GENEROUS Model, which applies MFN pricing to Medicaid drugs through state-invoiced rebates.

Informa's invitation-only Leadership Summit returns to CPHI Milan Oct. 6 as executives weigh sourcing, medicine security and reshoring pressure.

The EU's pharma reform makes market protection more conditional. Here is how US drugmakers, especially startups, can adapt and use IP to complement it.

The White House said Medicaid programs in all 50 states, D.C. and Puerto Rico now receive MFN prices, with nearly $65 billion in savings over a decade.

Rebate delays could force 340B hospitals to pay upfront and wait months for credit, distorting drug spend on the books. Valerie Bandy, PharmD, of Tecsys explains the fallout.

In this week's Pharma Pulse, Arkansas independent pharmacies bring an underpayment suit against Express Scripts, Novo Nordisk taps Anthropic for AI-driven drug discovery, and Sanofi, UCB and Opella join AstraZeneca on a supply chain heat decarbonization program.

DSCSA data exchange has matured into daily operations, but the coming NDC-12 shift and a national licensure standard add new work streams before old ones are fully settled.

Liberty Dewey of Cardinal Health breaks down the NDC-12 transition timeline, the four work streams driving it and why the biggest risk sits in trading partner handoffs.